Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eFT508 in Advanced Solid Tumors
NCT02605083Phase 2Terminated
- Sponsor
- eFFECTOR Therapeutics
- Start
- Dec 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tomivosertib in solid tumor, sponsored by eFFECTOR Therapeutics. Started Dec 2015; status: terminated.
02
Drugs
tomivosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02605083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02605083.